Name (Synonyms) | Correlation | |
---|---|---|
drug698 | DAS181 Wiki | 0.41 |
drug1822 | Placebo Wiki | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
D006973 | Hypertension NIH | 0.28 |
D002318 | Cardiovascular Diseases NIH | 0.21 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000822 | Hypertension HPO | 0.28 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.21 |
There is one clinical trial.
Hospitalized patients with COVID-19 will be included in the study in centers around Poland. After the hospitalization, a short questionnaire will be completed, including pre-hospitalization diagnoses, pre-hospitalization medications, clinical status on admission, the course, complication and the duration of hospitalization. The questionnaire will be available in paper form and on-line.
Description: Death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke
Measure: Adverse events Time: through study completion, an average of 2 weeksDescription: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints
Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke Time: through study completion, an average of 2 weeksDescription: Ventilation during hospitalization
Measure: Ventilation during hospitalization Time: through study completion, an average of 2 weeksDescription: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints
Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke Time: prolonged follow up, through study completion, an average of one year